Development and Prospective Randomized Evaluation of a Decision Aid for Prostate-specific Antigen-based Early Detection of Prostate Cancer in Men Aged Between 55 and 69 Yr: The PSAInForm Trial

Semjonow, Axel; Hense, Hans‐Werner; Schlößler, Kathrin; Simbrich, Alexandra; Borowski, Matthias; Bothe, Christiane; Kruse, K.; Tiedje, Dorothee; Kuss, Kathrin; Adarkwah, Charles Christian; Maisel, Peter; Jendyk, Ralf; Kurosinski, Marc-André; Gerß, Joachim; Heidinger, Oliver; Tschuschke, C.; Becker, Ralf; Roobol, Monique J.; Bangma, Chris H.; Donner-Banzhoff, Norbert

doi:10.1016/j.eururo.2019.01.008

Cited by 2 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They had to be aged 55 to 69 according to the core age group of the European Randomised Study of Screening for Prostate Cancer (ERSPC) 8 and had no history of PCa. Prior PSA testing was no exclusion criterion, but was documented 9 .…”

Section: Methodsmentioning

confidence: 99%

“…The DA “arriba-PSA” is one module of the library “arriba-lib” that contains several electronic DAs for the diagnosis, prevention and treatment of diseases (eg. cardiovascular prevention or atrial fibrillation) developed on best available evidence 9 – 11 . These modules are explicitly designed for a use during the consultation between physician and patient (“transactional”).…”

Section: Methodsmentioning

confidence: 99%

“…These modules are explicitly designed for a use during the consultation between physician and patient (“transactional”). As recommended by the International Patient Decision Aids Standards (IPDAS) the DA was designed and pre-evaluated within a multiple-step mixed-methods pilot study at the Department of General Practice Philipps-University Marburg, Germany 9 , 12 , 13 . After a qualitative field-test, the DA was modified according to user’s feedback.…”

Section: Methodsmentioning

confidence: 99%

“…The DA employs tables and pictograms, in which numerical information is presented for 1000 men with versus without PSA-based early detection (Fig. 1 ) 9 .

Figure 1 Pictogram of the “arriba-PSA”.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial

Tiedje¹,

Borowski²,

Simbrich³

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

International guidelines recommend to inform men about the benefits and harms of prostate specific antigen (PSA) based early detection of prostate cancer. This study investigates the influence of a transactional decision aid (DA) or cost compensation (CC) for a PSA test on the decisional behaviour of men. Prospective, cluster-randomised trial to compare two interventions in a 2 × 2 factorial design: DA versus counselling as usual, and CC versus noCC for PSA-testing. 90 cluster-randomised physicians in the administrative district of Muenster, Germany recruited 962 participants aged 55–69 yrs. in 2018. Primary endpoint: the influence of the DA and CC on the decisional conflict. Secondary endpoints: factors which altered the involvement of the men regarding their decision to take a PSA-test. The primary endpoint was analysed by a multivariate regression model. The choice to take the PSA test was increased by CC and reduced by the DA, the latter also reduced PSA uptake in men who were offered CC. The DA led to an increase of the median knowledge about early detection, changed willingness to perform a PSA test without increasing the level of shared decision, giving participants a stronger feeling of having made the decision by themselves. The DA did not alter the decisional conflict, as it was very low in all study groups. DA reduced and CC increased the PSA uptake. The DA seemed to have a greater impact on the participants than CC, as it led to fewer PSA tests even if CC was granted.Trial registration: German Clinical Trial Register (Deutsches Register Klinischer Studien DRKS00007687). Registered: 06/05/2015. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00007687.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…The DA employs tables and pictograms, in which numerical information is presented for 1000 men with versus without PSA-based early detection (Fig. 1 ) 9 .

Figure 1 Pictogram of the “arriba-PSA”.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial

Tiedje¹,

Borowski²,

Simbrich³

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…The multiphased PSA-inform project consisted of the development and user evaluation of a transactional DA for PSA screening (arriba-PSA), 36 followed by a later RCT 37 to, among other things, determine the influence of the transactional DA on men's decisional conflict.…”

Section: Designmentioning

confidence: 99%

Delivering the unexpected—Information needs for PSA screening from Men's perspective: A qualitative study

Kuss

Adarkwah

Becker

et al. 2021

Health Expectations

Self Cite

View full text Add to dashboard Cite

Background Making decisions about PSA screening tests is challenging, as it requires both knowledge of the possible benefits and harms of screening and an individual assessment of the patient's values. Our research explores how much and what information men perceive to be necessary with regard to screening for prostate cancer. Objective To explore men's information and associated needs for decision making in PSA testing. Design Qualitative interview study. Setting and participants We interviewed 32 men (aged 55‐69) about their decision making on PSA screening following counselling with a Decision Aid at their GP’s or urologist's practice in Germany. Main Outcome Measures Men's expressed needs for decision making in PSA testing. Methods All interviews were transcribed verbatim and analysed by framework analysis. Results Comprehensive pre‐screening counselling is needed. For the men in our study, information about test (in)accuracy, the benefit‐harm balance and consequences of the test were relevant and surprising. Additional needs were for interpretation support, a take‐home summary and time for deliberation. For several men, their physician's attitude was of interest. After being well‐informed, most men felt empowered to make a preference‐based decision on their own. Discussion Men were surprised by what they learned, especially regarding the accuracy and possible harms of screening. There is large variation in the breadth and depth of information needed, and some controversy regarding the consequences of testing. Conclusion and patient contribution A core set of information should be offered before men make their first PSA screening decision. Information about biopsy and associated side‐effects could follow in a short form, with details only on request. Knowledge about a high rate of false‐positive test results beforehand might help men handle a suspicious test result.

show abstract

Development and Prospective Randomized Evaluation of a Decision Aid for Prostate-specific Antigen-based Early Detection of Prostate Cancer in Men Aged Between 55 and 69 Yr: The PSAInForm Trial

Cited by 2 publications

References 7 publications

Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial

Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial

Delivering the unexpected—Information needs for PSA screening from Men's perspective: A qualitative study

Contact Info

Product

Resources

About